

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CNSX Issuer: BioNeutra Global Corporation (“BioNeutra” or the “Issuer”).

Trading Symbol: BGA

Number of Outstanding Listed Securities: 45,819,787 Common Shares

Date: December 2, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the [CNSX.ca](http://CNSX.ca) website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The terms “Issuer” and “BioNeutra” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**During the month of November, BioNeutra continued its focus on developing and manufacturing products for food and beverage companies operating in mainstream functional food and beverage markets. BioNeutra also continued its involvement in the research and development, production and commercialization of food ingredients for nutraceutical, functional and mainstream foods, with a focus on isomalto-oligosaccharides ("IMO").**

**BioNeutra also continued with the manufacturing and marketing of Vitafiber™ IMO in the North American and European markets. IMO-based products are widely used as prebiotics, fibers, low-calorie nutritive sweeteners and ingredients in functional foods, addressing numerous health issues relating to obesity, digestive health, cardiovascular disease, diabetes and oral health. Vitafiber™ is the only IMO product to have received US FDA GRAS, Health Canada and European EFSA approval as a Novel Food Ingredient.**

2. Provide a general overview and discussion of the activities of management.

**During the month of November, management met on a weekly basis to discuss sales and marketing trends, initiatives and plans. Management also completed required disclosure for the interim period ended September 30, 2015, including the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis.**

**Management continued the process of establishing a commercial IMO production line in its facility in Edmonton, Alberta. In November, Management continued the detailed production line design and planning process of the IMO production line.**

**Management also continued to work diligently to monitor the IMO marketplace worldwide for infringement of BioNeutra's intellectual property rights. In the event that management detects such an infringement of its rights, management acts promptly to assert and protect those rights.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**BioNeutra is constantly undertaking research and development initiatives to develop new IMO products, both for use by business-to-business customers as functional food and beverage ingredients and by consumers as functional food products. In November, no new products or services were offered to customers by BioNeutra, and in order to protect BioNeutra's intellectual property rights, products currently under development remain confidential.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**No products or services have been discontinued.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Not Applicable.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**Not Applicable.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Not Applicable.**

8. Describe the acquisition of new customers or loss of customers.

**On the retail side with respect to Amazon.com, BioNeutra continues to add customers through the natural evolution of such internet based retailing.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not Applicable.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not Applicable.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not Applicable.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**Not Applicable.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**Not Applicable.**

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance | Use of Proceeds |
|----------|---------------|---------------------|-----------------|
| N/A      |               |                     |                 |
|          |               |                     |                 |

15. Provide details of any loans to or by Related Persons.

**No loans to or by related party were incurred or repaid by BioNeutra during the month of November.**

16. Provide details of any changes in directors, officers or committee members.

**There were no changes to the Directors or Officers during the month of November.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Not Applicable**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 2, 2015.

Jianhua Zhu  
Name of Director or Senior Officer

(signed) "Jianhua Zhu"  
Signature

President & CEO  
Official Capacity

|  |  |                           |
|--|--|---------------------------|
| <b>Issuer Details</b><br>Name of Issuer                      | For Month Ended  | Date of Report<br>YY/MM/D |
| BioNeutra Global Corporation                                 | November 30, 2015                                      | 15/12/2                   |
| Issuer Address   |  |                           |
| 9608 25 Avenue NW  |  |                           |
| City/Province/Postal Code                                    | Issuer Fax No.   | Issuer Telephone No.      |
| Edmonton, Alberta, T6N 1J4                                   | (780) 801-0036   | (780) 466-1481            |
| Contact Name   | Contact Position                                       | Contact Telephone No.     |
| Bill Smith   | Chairman   | (780) 466-1481            |
| Contact Email Address  | Web Site Address                                       |                           |
| <a href="mailto:bsmith@bioneutra.ca">bsmith@bioneutra.ca</a> | <a href="http://www.bioneutra.ca">www.bioneutra.ca</a> |                           |